{
    "medicine_id": "c3a1de5334469c56511f6ee7752e01420d9136d2",
    "platform_id": "DB11597",
    "metadata": {
        "name": "Hyp Rho D Inj 16 5 1500 IU 2ml Injection solution",
        "composition": "1500 IU 2ml Human Rho D immune globulin",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for suppression of rhesus Rh isoimmunization in nonsensitized Rho D negative women with an Rh incompatible pregnancy or in Rho D negative individuals transfused with Rh0 D positive red blood cells RBCs or blood components containing Rh0 D positive RBCs Also indicated in Rh0 D positive non splenectomized adult patients with chronic immune thrombocytopenic purpura ITP to raise platelet counts",
            "contraindications": {
                "disease": "Most serious adverse reactions in patients with ITP include intravascular hemolysis anemia acute renal insufficiency and death In patients treated for Rh isoimmunization suppression common adverse effects include nausea dizziness headache pain at injection site and malaise Common adverse effects in patients with ITP include chills pyrexia mild extravascular hemolysis and headache",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "15000 international unit IU contains sufficient anti Rho D to effectively suppress the immunizing potential of approximately 17mL of Rho D D positive red blood cells L804 Human Rho D immune globulin therapy prevents immunization to Rho D positive red blood cells RBC by inducing antibody mediated immunosuppression AMIS effectively clearing Rho positive RBCs by rapidly binding to them This prevents Rho negative mothers to produce alloantibodies to paternally inherited RhD antigen expressed on fetal erythrocytes and cause haemolytic diseases of the newborn Rho immune globulin increase platelet counts and reduce bleeding in Rho positive patients with ITP by inhibiting autoantibody mediated platelet clearance",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}